Market Cap | 8.48M | P/E | - | EPS this Y | 79.00% | Ern Qtrly Grth | - |
Income | -11.5M | Forward P/E | -0.49 | EPS next Y | 35.30% | 50D Avg Chg | -7.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -18.00% |
Dividend | N/A | Price/Book | 0.52 | EPS next 5Y | - | 52W High Chg | -83.00% |
Recommedations | 2.50 | Quick Ratio | 4.26 | Shares Outstanding | 13.94M | 52W Low Chg | 49.00% |
Insider Own | 0.60% | ROA | -50.46% | Shares Float | 13.85M | Beta | 1.74 |
Inst Own | 1.30% | ROE | -105.38% | Shares Shorted/Prior | 182.09K/619.32K | Price | 0.34 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 333,608 | Target Price | 3.86 |
Oper. Margin | - | Earnings Date | Nov 12 | Volume | 141,325 | Change | -6.08% |
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device for cancer and life-threatening viral infections and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.
HC Wainwright & Co. | Buy | Jun 24, 24 |
HC Wainwright & Co. | Buy | Mar 4, 24 |
HC Wainwright & Co. | Buy | Oct 24, 23 |